Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.
Lishi LinEgbert F SmitAdrianus J de LangenDorieke E M van BalenJos H BeijnenAlwin D R HuitemaPublished in: Targeted oncology (2021)
The majority of the study population was not represented in the AURA3 trial. Survival outcomes of eligible patients are in concordance with the AURA3 trial, while OS of ineligible patients was significantly shorter compared to eligible patients.